1. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723.

  2. South San Francisco, CA: Genentech USA, Inc.; 2019.

  3. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2019.

  4. Liraglutide. Plainsboro, NJ: Novo Nordisk Inc.; 2019.

  5. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.

  6. Semaglutide. Plainsboro, NJ: Novo Nordisk Inc.; 2021.

  7. Tirzapatide. Indianapolis, IN: Eli Lilly and Company; 2021.

  8. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.

  9. Bray GA, Ryan DH. Medical therapy for obesity: a review of the long-term studies of drugs approved by the U.S. Food and Drug Administration. Obesity (Silver Spring). 2009;17(1):1-8.

  10. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616.

  11. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.

  12. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943.

  13. Kühnen P, Krude H, Biebermann H. Melanocortin-4 receptor agonists for the treatment of obesity. Curr Opin Endocrinol Diabetes Obes. 2019;26(5):248-253.

  14. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.

  15. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699.

  16. Zijlmans WC, Bakker CM, de Geus-Oei LF, et al. Preoperative prediction of the effect of bariatric surgery on obesity-related diseases: a systematic review. Obes Surg. 2016;26(8):2053-2064.

  17. Nguyen NT, Masoomi H, Laugenour K, et al. Predictive factors of mortality in bariatric surgery: data from the Nationwide Inpatient Sample. Surgery. 2011;150(2):347-351.

  18. Frias, J. P., Nauck, M. A., Van, J., et al. (2020). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet, 396(10267), 2020, 1695-1705.